Weight-loss drugmaker Novo Nordisk invests $1.2 bn in new factory in Denmark
Danish pharmaceutical giant Novo Nordisk, maker of diabetes and weight-loss treatments Ozempic and Wegovy, said Monday it was investing 8.5 billion kroner ($1.2 billion) to build a new factory in Denmark to produce drugs against rare diseases.
Eli Lilly (LLY 0.86%) and Novo Nordisk (NVO -1.53%) have competed for decades. They're both leaders in the areas of insulin ...
Novo Holdings can proceed with its planned $16.5 billion acquisition of Catalent after U.S. regulators declined to challenge ...
The $16.5 billion take-private deal can now be completed, and along with it Novo Nordisk’s related acquisition of three ...
3don MSN
It’s quickly become evident that GLP-1 drugs for diabetes, weight loss, and more are the new wonder drugs—if only people ...
Novo Nordisk currently controls approximately 55% of shares in the diabetes and obesity market through drugs like Ozempic ...
The proposed buyout of contract drug manufacturer Catalent won’t raise competition concerns, the European Commission said.
NVO's CagriSema target of up to 25% in long-term weight loss is highly promising vs. 15% through Wegovy and 20% through ...
Eli Lilly's popular weight-loss drug Zepbound outperformed Danish drugmaker Novo Nordisk's Wegovy in a clinical trial, ...
Wegovy and other GLP-1 medications have become extremely popular over the past few years. Novo Nordisk (which makes both ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback